Coretech 5

MLCOT

FR0013371507

Real-time Euronext Paris Other stock markets 03:00:27 27/06/2024 pm IST			5-day change	1st Jan Change
0.025 ^EUR	-.--%		-16.67%	+400.00%

2023	Gour Medical SA announced that it has received â‚¬0.135 million in funding	CI
2023	Gour Medical SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Gour Medical SA announced that it has received â‚¬0.135 million in funding

July 10, 2023

Gour Medical SA announced a private placement of 3,375,000 shares at a price of â‚¬0.04 per share for gross proceeds of â‚¬135,000 on July 10, 2023.

Latest news about Coretech 5

Gour Medical SA announced that it has received â‚¬0.135 million in funding	10/23/10	CI
Gour Medical SA Reports Earnings Results for the Full Year Ended December 31, 2022	08/23/08	CI
Gour Medical SA cancelled its agreement to acquire Worldwide Rights to a dual orexin receptor antagonist from Actelion Pharmaceuticals Ltd.	10/16/10	CI
Actelion Pharmaceuticals Ltd entered into a definitive worldwide license agreement to acquire Worldwide Rights to a dual orexin receptor antagonist from Gour Medical SA.	10/15/10	CI

Coretech 5 specializes in the development and commercialization of innovative veterinary solutions for the management of the main pathologies of companion animals. Its unique positioning is based in particular on the use of natural products based on hemp extracts. Devoid of psychoactive effects, WEEDLEY, its first range of premium solutions, increases the effectiveness of cannabidiol thanks to the surround effect.

Sector

More about the company